Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | CHIEF MEDICAL OFFICER | February 17, 2026 | February 19, 2026 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Chief Medical Officer | March 30, 2022 | March 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DELCATH SYSTEMS, INC.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.40 · Expires 2036-02-17 | Direct | 56,500 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 56,500 · Balance 56,500 F1: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 28,250 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 28,250 · Balance 28,250 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F3: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended).
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F3: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
Rein Therapeutics, Inc.
Report date March 30, 2022 · Filed March 30, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2032-03-29 | Direct | 150,000 |
Reported balance
After 2022-03-30 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-30 · Grant · Acquired 150,000 · Balance 150,000 F1: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022. F2: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022.
F2: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantRestricted Stock Units · Derivative | 28,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001466794-26-000003 · form4-02182026_090205.xml · derivative · entry 2 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,250 Underlying: Common Stock · 28,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 56,500 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001466794-26-000003 · form4-02182026_090205.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires 2036-02-17 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 21:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001415889-25-017260 · form4-06132025_090639.xml · derivative · entry 2 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 42,000 shares Expires 2034-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 12, 2024 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 21:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | Exercise / conversionCommon Stock | 42,000 | $4.78 | $200,760.00 |
DisclosureSEC source: 0001415889-25-017260 · form4-06132025_090639.xml · nonDerivative · entry 1 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 8, 2025 00:06 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 113,000 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0001415889-25-003404 · form4-02082025_120239.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2035-02-07 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 21:03 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantCommon Stock | 26,882 | $3.72 | $100,001.04 |
DisclosureSEC source: 0001415889-24-008588 · form4-03192024_090356.xml · nonDerivative · entry 1 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,882 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:46 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 100,500 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001415889-24-003763 · form4-02142024_090238.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2034-02-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 12, 2024 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:20 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 40,000 | $3.00 | $120,000.00 |
DisclosureSEC source: 0001209191-23-058628 · doc4.xml · nonDerivative · entry 1 Vukovic Vojo · CIK 0001466794 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 60,000 | $2.48 | $148,800.00 |
DisclosureSEC source: 0001209191-23-056054 · doc4.xml · nonDerivative · entry 1 Vukovic Vojo · CIK 0001466794 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.41 to $2.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 30, 2022 Filed Mar 30, 2022 20:32 UTC Amendment | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-22-012857 · doc4a.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-29 F1 · date: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 19:43 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-012144 · doc4.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-21 F1 · derivative.exercise_date: This option was granted on March 22, 2022. The shares underlying the option are scheduled to vest in equal monthly installments through March 22, 2026. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 19:51 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024524 · doc4.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest as to 25% of the shares on June 15, 2022 and thereafter in equal monthly installments through June 15, 2025. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:33 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-20-002807 · doc4.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: This option was granted on January 31, 2020. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 31, 2020. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 16:17 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 75,000 | $0.59 | $44,452.50 |
DisclosureSEC source: 0000899243-19-022104 · doc4.xml · nonDerivative · entry 1 Vukovic Vojo · CIK 0001466794 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5890 per share to $0.5980 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 18:43 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-19-010815 · doc4.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 18:18 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0000899243-18-028339 · doc4.xml · derivative · entry 1 Vukovic Vojo · CIK 0001466794 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-11-04 F1 · derivative.exercise_date: This option was granted on November 5, 2018. The shares underlying the option are scheduled to vest as to 25% of the shares on November 5, 2019 and thereafter in equal monthly installments through November 5, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.